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tion into the human genome has been considered as one of the
major causative factors to hepatocarcinogenesis, the underlying
mechanism(s) was still elusive. Here we investigate the essential
difference(s) of HBV integration between HCC tumor and adja-
cent non-tumor tissues and explore the factor(s) that determine
the oncogenicity of HBV integration.
Methods: 1115 HBV integration sites were collected from four
recent studies. Functional annotation analysis of integration tar-
geted host genes (ITGs) was performed using DAVID based on
Gene Ontology and KEGG pathway databases. Array-based
expression proﬁles, real-time qPCR and western blot were used
to detect the expression of recurrent integration targeted genes
(RTGs). The biological consequences of the overexpression of
UBXN8 in 8 HCC cell lines were studied in vitro.
Results: HBV is prone to integrate in genic regions (exons,
introns, and promoters) and gene-dense regions. Functional
annotation analysis reveals that, compared to those in adjacent
non-tumor tissues, ITGs in HCC tumor tissues were signiﬁcantly
enriched in functional terms related to negative regulation of cell
death, transcription regulation, development and differentiation,
and cancer related pathways. 32% of the 75 RTGs identiﬁed in thisJournal of Hepatology 20
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RTGs, was identiﬁed as a new tumor suppressor candidate which
functions in a TP53 dependent manner.
Conclusions: The oncogenicity of HBV integration was deter-
mined, to some extend by the function of HBV integration tar-
geted host genes in HCC.
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Hepatocellular carcinoma (HCC) is the third leading cause of
global cancer deaths [1]. Chronic infection with hepatitis B virus
(HBV) is one of the major risk factors for the development of HCC,
particularly in China where more than 80% of HCCs have been
associated etiologically with HBV [2]. It has been widely recog-
nized that HBV DNA integration into the genome of hepatocytes
is one of the major causes of hepatocarcinogenesis [3–6]. There
were two main promulgated mechanisms explaining the oncoge-
nicity of HBV integration in hepatocarcinogenesis: (1) the
inserted fragments of the HBV genome themselves have strong
oncogenic potency due to mutational changes, such as the
truncation of the viral HBx protein; (2) viral DNA integration
promotes carcinogenic changes in the host genome, including
inducing chromosome instability, nearby cellular genes aberrant
expression and interruptions of the normal structure of host
genes leading to their functional aberration. Recent work from
this lab has revealed that the characteristics of the oncogenic
elements contained in inserted HBV sequences were similar
between tumor and adjacent non-tumor tissues [7], suggesting
the oncogenicity of HBV integration resides primarily in its
effects on the host genome. The potential for HBV integration
events to cause aberrant regulation of the expression of nearby
host genes and to induce vicinal chromosome instability has
already been conﬁrmed by a number of studies [7–9].
Recently, several research groups have reported a large
number of HBV integrations in HCC through the application of
next generation sequencing (NGS) [8–12], which provided us14 vol. 60 j 975–984
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the relatively unbiased and unprecedented great amount of infor-
mation about HBV integration. A few frequently targeted genes
such as hTERT, MLL4, and CCNE1 have been noted [9–11]. More-
over, Murakami et al. [12] and Ding et al. [11] have suggested that
host genes potentially affected by HBV integration in HCC tissues
were enriched in distinct functions. However, those frequently
targeted genes accounted for only 7% of the total integration
events characterized. The oncogenic potential of the remaining
90% of the HBV integration events deﬁned to date remains largely
unattached. Alongside this, the frequent occurrence of HBV inte-
gration events in adjacent non-tumor tissues has also been
reported [8–11]. However, the functions of those potentially inte-
gration targeted genes derived from adjacent non-tumor have
never been characterized. Combining the NGS data with the
231 virus-human DNA junctions analyzed by this lab [7], a total
of 1115 HBV integration sites have now been characterized.
In the present study, we take advantage of the availability of
this large body of information on HBV integration to investigate
the differences in the patterns of HBV integration events seen
in HCC and adjacent non-tumor tissues, as well as to analyze
the distinct functions of integration targeted host genes (ITGs)
from HCC tumor tissues using gene function annotation analysis.
The cancer relativities of the recurrently targeted host genes
(RTGs) of HBV integration were further analyzed. And the tumor
suppressor property of UBXN8, one of the RTGs, was identiﬁed for
the ﬁrst time.Materials and methods
Patient specimens and HCC cell lines
49 pairs of matched primary human HCC tumorous and corresponding adjacent
non-tumorous tissue samples were obtained from patients, who underwent sur-
gical resection in the Afﬁliated Oncology Hospital of Zhengzhou University
between March and April 2013, and have been histologically conﬁrmed. Clinical
features of the patients are presented in Supplementary Table 1. HCC cell lines
HepG2, Hep3B, HuH1, HuH7, SMMC7721, SNU182, SNU387, SNU449, PLC/PRF/5
and one endothelial cell line Sk-Hep-1 (which was derived from hepatic ascites
adenocarcinoma) used in the study were stored by our lab and have been previ-
ously used.
This study was approved by the Ethics Committee of Peking University Health
Science Center. Informed consent was obtained from each participant.
Modiﬁed read number
To compare the supported read number of virus-host junctions detected by NGS
with different coverage. We modiﬁed the read number according to the coverage
of the corresponding NGS method as following:
In 30 NGS, modiﬁed read = original read  8;
In 80 NGS, modiﬁed read = original read  3;
In 240 NGS, modiﬁed read = original read  1.
The modiﬁed read number of each integration site can be accessed in Supplemen-
tary Table 4.
EST proﬁles data source and metabolically related genes
EST (expressed sequence tag) proﬁles of liver tissues were downloaded from Uni-
Gene (http://www.ncbi.nlm.nih.gov/unigene/). The EST proﬁles show approxi-
mate gene expression patterns as inferred from EST counts and the cDNA
library sources. The expression level of each gene is presented as transcripts
per million (TPM), meaning the number of transcripts belonging to the gene in
every one million clones.976 Journal of Hepatology 201Genes belonging to the Gene Ontology (GO) terms of metabolic processes that
take place in liver were abstracted from the human genome and deﬁned as met-
abolically related genes, and downloaded from the GO database (http://
www.geneontology.org/). These metabolic processes included protein metabo-
lism (GO:0019538), lipid metabolism (GO:0006629), carbohydrate metabolism
(GO:0005975), vitamin metabolism (GO:0006766), hormone metabolism
(GO:0042445), and RNA and DNA metabolism (GO:0016070 and GO:0006259).
Integration targeted genes (ITGs)
The HBV integration sites were mapped to the human genome (hg19) as their
source publication reported. Genes with their transcription start sites (TSS) clos-
est to the HBV integration sites (with distance 61 Mb from integration site) were
deﬁned as integration targeted genes (ITGs) (Table 1; Supplementary Table 2).
RefSeq genes were used as the reference database.
Chromosome aberration detection and RNA expression proﬁles
Chromosome aberration analyzed via array-based Comparative Genomic Hybrid-
ization (aCGH) assays of 25 HCC tumor tissues has been previously described [7].
Six of the above 25 paired HCC tumor and non-tumor tissues were used in the
RNA expression proﬁles (Arraystar Human LncRNA Microarray v2.0). Subsequent
data analysis was carried out using Agilent Feature Extraction. Paired t test was
used to statistically identify the abnormally expressed genes in HCC. A p value
<0.05 and greater than 2-fold change were the criteria of differently expressed
genes.
Gene functional annotation analysis
DAVID (http://david.abcc.ncifcrf.gov/) [13,14] was used to perform the gene func-
tional annotation analysis, the categories of GO and KEGG Pathways were chosen
as background databases. All genes of homo sapiens were used as background
gene list.
RNA extraction and real-time qPCR
Real-time qPCR was performed as previously described [15]. Primers and anneal-
ing temperatures for different genes are listed in Supplementary Table 3.
In vitro functional experiments
Lentivirus expression system was used to restore the expression of UBXN8 in HCC
cell lines. The methods of Western blot, MTT assay and ﬂow cytometry technique
were described previously [15,16].
Statistical analysis
All the statistical analyses were performed using SAS 9.1 for windows. The v2 test
and Fisher’s exact tests were used to compare categorical variables between two
groups. The Mann-Whitney test was used to analyse the differences between dif-
ferent groups of discrete variables. Student’s t test was used to compare two
groups of continuous variables. All estimates were accompanied by a 95% conﬁ-
dence interval, where a p <0.05 was considered as being statistically signiﬁcant.Results
Cataloguing the ensemble of HBV integration sites
All of the virus-host junctions from the three NGS studies [8–10],
together with those from the PCR based study of this lab [7] were
aggregated as an ensemble. Virus-host junctions detected in a
number of earlier studies which could not be precisely mapped
to human genome were not included [17–20]. A total of 1115
integration sites from 155 HCC patients were taken into the anal-
ysis. Among them, 1004 sites were unique (Table 1, Supplemen-
tary Table 4). The clinical features of the 74 patients with detailed4 vol. 60 j 975–984
Table 1. The ensemble of integrated sites and the contents of different subgroups.
Methods [Ref.] Sample count Integration count Subgroup A- 
non-repetitive
Subgroup B
T NT T NT Functional
annotation
ITG count
T NT
PCR [7] 60 60 80 151 Y Y 78 148
NGS 30× [9,10] 92 81 299 52 Y Y 292 50
NGS 80× [8] 3 3 148 107 Y# Y 144 106
NGS 243× [8] 1 1 142 136 Y - - -
Total 155 144 669 446 1004 837 514 304
Subgroup A, non-repetitive; all non-redundant integrations.
Subgroup B, functional annotation; integration sites used in functional annotation.
#Integration sites detected in sample 31656 by NGS 80 were excluded, because sample 31656 was also used in NGS 243.
PCR, technique of Alu-/LM-PCR [7]; NGS, next generation sequencing; ; NGS coverage; T, HCC tissues; NT, adjacent non-tumor tissues; ITG, integrated targeted host genes;
Y, integration sites detected by the certain methods were included in the subgroups.
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Fig. 1. HBV break points distribution and the percentages of integrated viral fragments containing transcriptional regulators. T, tumorous tissues; NT, non-tumorous
tissues. (A) Distribution of HBV break points across the HBV genome. This ﬁgure only included sites from C genotype. For B and D genotypes please refer to Supplementary
Fig. 1. (B) Percentage distribution of HBV break points in the three regions of the viral genome. (C) Correlation between the lower limit of modiﬁed read numbers of
integration events and the percentages of them with break points located in the DR2-DR1 region. e.g.: the point (X = 5, Y = 32%) means 32% of HBV break points of the
integration event supported byP5 modiﬁed reads located in DR2-DR1 region. (D) The percentages of inserted viral fragments containing transcriptional regulators. n.s., not
signiﬁcant. (This ﬁgure appears in colour on the web.)
JOURNAL OF HEPATOLOGYpatient by patient information are summarized in Supplementary
Table 5; the summary of integration status of the overall 155
patients is presented in Supplementary Table 6. The average inte-
gration sites in tumor tissues and non-tumor tissues are
4.04 ± 12.97 and 2.63 ± 11.58 (mean ± SD), respectively. To inves-
tigate and compare different characteristics of the HBV integra-
tion seen in HCC and adjacent non-tumor tissues, different
subgroups of this ensemble were used (Table 1).Journal of Hepatology 201Viral transcriptional regulators are frequently present in integrated
HBV fragments from both tumor and adjacent non-tumor tissues
The HBV breakpoints distribution of 1004 non-redundant inte-
gration events (Table 1, subgroup A) was analyzed. In agreement
with previous reports [8,9], 37% of the HBV break points were
mapped within the DR2-DR1 region (1590–1840 nt) of the HBV
genome. (Fig. 1A, Supplementary Fig. 1). Especially for the DR14 vol. 60 j 975–984 977
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Fig. 2. The distribution of HBV integration events in the human genome. T,
tumorous tissues; NT, non-tumorous tissues. (A and B) Percentages of HBV
integration sites located within genes and promoters. (C and D) Number of host
genes located within 100 kb surrounding each HBV integration site. Data were
presented in boxes and whiskers’ style, representing the ranges and medians of
the data. (E) Transcriptional activities of host genes located within 15 kb
surrounding HBV integration sites. ‘TPM’ indicates the expression level of genes
in normal liver tissues. The whiskers represent the 2.5–97.5 percentile of the data.
(F) The percentage of sites located nearby 15 kb surrounding metabolism-related
genes.
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(1820–1840 nt) region, 11% of the break points were mapped
within. We noticed the relatively even distribution of viral break-
points in HCC tumor tissue compared to that in adjacent non-
tumor tissues (28% vs. 51% localized within the DR2-DR1 hotspot;
p <0.0001; Fig. 1B). Interestingly, when the modiﬁed read number
(see Materials and methods section) derived from NGS data was
considered, there was a positive correlation between the percent-
age of viral break points localized in the DR2-DR1 hotspot and the
lower-threshold of modiﬁed read numbers (R2 = 0.85, p <0.0001;
Fig. 1C). The same tendency could be observed when analyzed
using the original reads number in each depth of NGS methods
(NGS30, NGS80, and NGS240; Supplementary Fig. 2).
The preference of HBV break points distributed in the DR2-
DR1 region may imply a large proportion of inserted HBV
sequence containing viral transcriptional regulators. Indeed,
detailed analysis of the inserted viral fragments detected by
PCR methods [7] revealed the similar frequencies of truncated
HBx gene (>90%) and intact enhancer II (>40%) both in HCC tumor
and adjacent non-tumor tissues. Although a greater percentage of
the integration events in HCC tissues contained intact basic core
promoter (BCP), the difference was not statistically signiﬁcant
(p = 0.12; Fig. 1D).
HBV integration sites are preferentially located in genic regions and
gene-dense regions
To investigate the distribution pattern of integration sites in the
human genome, 1004 non-repetitive integration sites were ana-
lyzed. Almost 45% of them were located in gene-coding regions
(including exons and introns), which was signiﬁcantly enriched
compared to the expected ratio based on the fraction of the
human genome compassion of such regions (39%; v2 test,
p = 0.0114). More reﬁned analysis revealed that the 1004 sites
were preferentially located in exons and promoters (deﬁned as
the 0–5 kb upstream region of genes’ TSSs) compared to expected
frequencies (Fig. 2A). Further stratiﬁed analysis revealed that the
integration events derived from HCC tumor tissues prominently
located in exons or promoter regions (p = 0.025), whilst the
non-tumor derived events were found signiﬁcantly enriched in
introns (p = 0.0003) (Fig. 2B).
It has been suggested that the open chromatin conﬁguration,
where genes are enriched and characterized by active regulation
or transcription, is more accessible to HBV integration. To testify
this prediction, 1000 sites across the human genome were
selected randomly as a control group. Then the number of genes
in a region of 100 kb up and downstream of both the 1004 inte-
gration sites and 1000 random sites was catalogued. A total of
2730 genes were identiﬁed surrounding the 1004 integrated
sites, while only 1997 genes were found in the random group
(Mann-Whitney test, p <0.0001, Fig. 2C). Unexpectedly, no signif-
icant difference between HCC tumor and adjacent non-tumor tis-
sues was observed (Fig. 2D).
We next tested the status of active regulation or transcription
of host genes surrounding integration sites. To analyze this, TPM
values from EST proﬁles in normal liver tissues (see ‘Materials
and methods’ for details) were used as a direct indicator of nor-
mal transcriptional activity of host genes. Within 15 kb upstream
or downstream of the 1004 integration sites and 1000 randomly
selected sites, a total of 837 genes and 631 genes were identiﬁed
from human genome, respectively. The expression levels of genes
in the HBV integration group were higher than those in the978 Journal of Hepatology 201random group, but the difference was not statistically signiﬁcant
(Fig. 2E). However, when we compared this in HCC tumor and
adjacent non-tumor groups separately, it showed that the genes4 vol. 60 j 975–984
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from the adjacent non-tumor group had signiﬁcantly higher
expression levels compared to those both in the random group
and HCC tumor group (Mann-Whitney test, p <0.0001; Fig. 2E).
In addition and somewhat unexpectedly, the expression levels
of surrounding genes for the HCC tumor group were signiﬁcantly
lower than those seen in the control random group (p = 0.009;
Fig. 2E). Similar results were obtained when the analysis window
was expanded from 15 kb to 50 or 100 kb (data not shown). Sub-
sequent analysis showed that, in comparison to HCC tumor tis-
sues, a signiﬁcant larger percentage of integration sites were
located in the 15 kb upstream and downstream regions of meta-
bolically related genes (see Materials and methods for deﬁnition)
in adjacent non-tumor tissues (T: 20% vs. NT: 30%; v2 test,
p <0.0001; Fig. 2F).
Functional annotation analysis shows a distinct clustering of gene
functions for HBV integration targeted genes (ITGs) identiﬁed in HCC
derived tissues
As the results above indicated that the characteristics of host
genes surrounding integration sites may have signiﬁcant differ-
ences between HCC and adjacent non-tumor tissues, identifying
the functions of the host genes targeted by HBV integration
events could be important in understanding the process of21.2
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Fig. 3. Functional annotation analysis of HBV integration targeted genes (ITGs). (A) F
Functional annotation analysis of ITGs from both high clonal expansion group and low
Table 2. The enriched GO terms and KEGG pathways of 75 recurrently targeted gene
GO ID Term
GO:0032502 Developmental process
GO:0007275 Multicellular organismal developme
GO:0030154 Cell differentiation
GO:0045941 Positive regulation of transcription
GO:0010628 Positive regulation of gene express
GO:0045893 Positive regulation of transcription, 
Positive regulation of gene-specificGO:0043193
GO:0030182 Neuron differentiation
KEGG ID Term
hsa04070 Phosphatidylinositol signaling syste
hsa05222 Small cell lung cancer
Count, number of RTGs belonging to each term; %, percentage of genes belonging to eac
Journal of Hepatology 201carcinogenesis associated with HBV integration. To address this
concern, we conducted ITGs functional analysis using the DAVID
software. A total of 817 ITGs at 837 integration sites from sub-
group B were identiﬁed (Table 1). Among them, 87.4% of the ITGs
were located within 100 kb from the integrated sites, of which
38.7% had integration sites within them or in their promoters
(Supplementary Table 2). Because it has been reported that
inserted HBV fragments were able to activate promoters up to
100 kb away [21,22], this observation implies that the majority
of ITGs could be affected by HBV integration.
Gene ontology analysis of the 408 non-redundant ITGs from
the HCC tissues revealed that terms related to developmental
process and cell differentiation, transcriptional regulation, cell
communication and negative regulation of cell death were signif-
icantly enriched (p <0.05). In the pathway annotation analysis, 5
ITGs in the HCC tumor group belonged to ‘‘Prostate cancer’’
(p = 0.049; Fig. 3A, Supplementary Table 6). The annotation of
the 274 unique ITGs from the adjacent non-tumor tissues showed
they were enriched in terms related to developmental process
and cell differentiation, cell communication and transcriptional
regulation too, but with signiﬁcantly smaller percentages
(Fig. 3A and Supplementary Table 8). In addition, the ITGs in
the non-tumor group were not enriched in terms related to neg-
ative regulation of cell death or cancer related pathways. Instead,19.6
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Count % p value
17 23.29 1.21E-02
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3 4.11 2.72E-02
5 6.85 3.96E-02
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m 3 4.11 3.67E-02
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Table 3. The 40 RTGs with frequent CNVs or aberrant expression in HCC.
Gene 
symbol
Integration sites 
counts
Deletion/ Expression 
tendency
Total Tumor Non-
tumor
total cases 
n = 25
TERT 25 25 0 3/6 T >NT
MLL4 10 10 0 2/8 T >NT
CCNE1 7 7 0 0/3 T >NT
ANKRD26P1 4 4 0 5/0 T = NT
SENP5 3 3 0 2/4 T >NT
HRSP12 3 2 1 1/7 T<NT
SLITRK6 3 2 1 4/0 T <NT
FGF9 2 2 0 2/1 T <NT
RIMS1 2 2 0 4/3 T = NT
RPP40 2 2 0 1/6 T >NT
FAM46C 2 2 0 2/4 T <NT
RIPK2 2 2 0 1/4 T = NT
TUFT1 2 2 0 0/14 T >NT
EBF3 2 2 0 4/1 T = NT
OR51E1 2 2 0 4/3 T >NT
SPRYD4 2 2 0 1/4 T <NT
C1QTNF9 2 2 0 5/1 T = NT
C1orf229 2 2 0 1/8 T = NT
NBAS 2 2 0 1/2 T >NT
MIR764 2 2 0 6/3 T = NT
ARHGEF10L 2 2 0 8/2 T = NT
ADH1A 2 2 0 12/0 T <NT
UBXN8 2 2 0 7/0 T <NT
DDX54 2 2 0 0/2 T <NT
TC2N 2 2 0 7/1 T = NT
CSMD1 3 0 3 10/0 T = NT
EIF4B 2 0 2 3/6 T <NT
ESRRG 2 0 2 1/12 T = NT
DGKG 2 0 2 0/3 T <NT
LAMP1 2 0 2 7/5 T >NT
FN1 21 2 19 7/2 T >NT
C3orf58 2 1 1 0/2 T <NT
GTF2I 2 1 1 0/2 T >NT
PIK3R1 2 1 1 0/0 T <NT
LPHN3 2 1 1 6/2 T = NT
CASP12 2 1 1 4/2 T = NT
SMARCA1 2 1 1 6/3 T = NT
C4orf51 2 1 1 7/0 T = NT
C1GALT1 2 1 1 2/4 T = NT
GALC 2 1 1 6/0 T = NT
amplification
Gene symbols in bold indicate the 12 genes never reported to be cancer related.
Deletion/ampliﬁcation indicates the results of aCGH assays.
Expression tendency results in bold were detected by qPCR.
T, HCC tumorous tissues; NT, adjacent non-tumorous tissues.
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they were enriched in terms related to cell adhesion and immune
response (Fig. 3A).
The modiﬁed read number representing an integrated
sequence derived from NGS data was assumed to reﬂect the clo-
nal expansion ability of cells harboring this HBV integration site.
In order to isolate functional terms closely related to hepatocyte
malignant transformation, we next investigated whether the
ITGs’ enriched functional terms would change along with the
extent of clonal expansion after HBV integration. Based on the
above assumption, ITGs of the integration sites from HCC tissues
were divided into two subgroups: 193 ITGs derived from viral-
host junction sites supported by <32 modiﬁed reads in NGS were
regarded as the low clonal expansion group; 235 ITGs of sites
supported by P32 modiﬁed reads in NGS and those detected
by PCR were regarded as the high clonal expansion group. (Sites
from the PCR method were catalogued as high read events
because sensitivity of the PCR method is much lower than NGS.
The read number 32 was chosen as the cut-off value because it
was the median of modiﬁed reads after considering the sites from
PCR and could balance the number of sites in either group.) Func-
tional annotation showed that greater percentages of genes were
enriched in terms related to transcriptional regulation, negative
regulation of cell death, and prostate cancer pathway in the high
clonal expansion group (Fig. 3B, Supplementary Table 9); In con-
trast, genes from the low clonal expansion group were no longer
enriched in the above three catalogues of terms. But they were
enriched in the ‘‘aging’’ (p = 0.014) and ‘‘negative regulation of
Wnt receptor signaling pathway’’ (p = 0.027; Supplementary
Table 10). ITGs from both groups were enriched in terms related
to developmental process and cell differentiation. Therefore,
functional terms of transcriptional regulation, negative regula-
tion of cell death, cancer pathways, and developmental process
and cell differentiation were deﬁned as integration related onco-
genic functions (IROFs). We suggested that affecting the expres-
sions or functions of genes with IROFs is the determined
oncogenic factor of HBV integration. Consistent with this hypoth-
esis, the percentages of tissues containing ITGs annotated in the
IROFs were signiﬁcantly higher in HCC tumor tissues (T: 73% vs.
NT:20%; p <0.0001).
We also performed functional annotation analysis on 256
genes recurrently mutated (mutated more than once) in HCCs
[10,23]. The results revealed that functional terms belonging to
three IROFs, with an exception of ‘transcriptional regulation’,
could be found in the top 30 enriched GO terms and the top 5
enriched KEGG pathways (Supplementary Table 11), indicating
that genes related to IROFs were indeed functioning abnormally
in HCC.
Genes recurrently targeted by HBV integration are potentially cancer
related
A number of studies have suggested that HBV integration can
induce tumorigenesis through affecting few frequently targeted
genes relevant to neoplasia, including hTERT, MLL4, and CCNE1
[24–27]. Though these three frequently identiﬁed ITGs were
detected in up to 31% of the HCC samples analyzed in this study,
the cancer related functions of ITGs from the remaining 70% of
HCC tissues have been overlooked, particularly those where
genes have been integration targeted more than once (deﬁned
as recurrently targeted genes, RTGs). In this study, overall 75
RTGs were identiﬁed amongst all the 817 ITGs. The functional980 Journal of Hepatology 201annotation analysis of these 75 genes showed they were mainly
enriched in terms belonging to IROFs (Table 2). Besides, the result
of our aCGH assays showed that 33 (44%) of the 75 RTGs exhib-
ited copy number variations (CNVs) in no less than 20% (5/25)
of the HCC tissues (Table 3). Even more, scrutiny of the documen-
tation concerning the 75 RTGs showed that 26 (35%) of them have
been reported to be cancer related genes. Additionally, the results4 vol. 60 j 975–984
Eiii
Eii
Ei
Diii
Dii
Di
C
Biv
A
UBXN8
ATG TAG
Ex 1 Ex 2 Ex 3 Ex 4 Ex 5 Ex 6 Ex 7 Ex 8
Integrated site: 
chr8: 30611415
Integrated site: 
chr8: 30614167
G1:
S:
G2:
50.42%
37.19%
12.39%
G1:
S:
G2:
57.69%
29.68%
12.63%
G1:
S:
G2:
70.51%
12.10%
17.38%
G1:
S:
G2:
60.47%
25.84%
13.69%
HepG2
N
um
be
r
Channels (FL2-A)
N
um
be
r
Channels (FL2-A)
N
um
be
r
Channels (FL2-A)
G1:
S:
G2:
48.46%
40.62%
10.93%
G1:
S:
G2:
50.12%
36.75%
13.13%
HepG2 control HepG2 UBXN8
Sk-Hep-1 control
Sk-Hep-1
Sk-Hep-1 UBXN8
HuH7 control
HuH7
HuH7 UBXN8
p53
CCND1
p21
UBXN8-myc
α-tubulin
p53
CCND1
p21
UBXN8-myc
α-tubulin
CCND1
p21
UBXN8-myc
α-tubulin
TP53 w
ild-type
TP53 m
utant
UB
XN
8
Co
ntr
ol
UB
XN
8
Co
ntr
ol
UB
XN
8
Co
ntr
ol
Bi
0.6
0.4
0.2
0.0
0.5
0.4
0.3
0.2
0.1
0.0R
el
at
iv
e 
ex
pr
es
si
on
 
of
 U
B
X
N
8 
(2
-∆
ct
)
Normal
n = 14
TumorNon-tumor
n = 49
0.25
0.20
0.15
0.10
0.05
0.00R
el
at
iv
e 
ex
pr
es
si
on
 
of
 U
B
X
N
8 
(2
-∆
ct
)
S
M
M
C
77
21
H
uH
7
P
lc
5/
pr
f/5
H
ep
G
2
H
ep
3B
S
nu
18
2
S
nu
38
7
S
nu
44
9
S
nu
47
5
S
k-
H
ep
-1
p = 0.035
p <0.0001
p = 0.0003
UBXN8 BiiiBii
R
el
at
iv
e 
U
B
X
N
8 
m
R
N
A 
le
ve
l Tumor
Non-tumor
150C 150P 192C 192P
370C 370P 379C 379P
380C 380P 3C 3P
UBXN8
GAPDH
UBXN8
GAPDH
UBXN8
GAPDH
HepG2 control
HepG2 UBXN8
Day
*** ***
**
5
5
4
4
3
3
2
2
1
1
0
0
R
el
at
iv
e 
M
TT
 a
bs
or
ba
nc
e HepG2 control
HepG2 UBXN8
Day
***
***
**
5
5
4
4
3
3
2
2
1
1
0
0
R
el
at
iv
e 
M
TT
 a
bs
or
ba
nc
e Sk-Hep-1 control
Sk-Hep-1 UBXN8
Day
8
5
6
4
4
3
2
21
0
0
R
el
at
iv
e 
M
TT
 a
bs
or
ba
nc
e HuH7 control
HuH7 UBXN8
80
60
40
20
0
G1 S G2/M
P
er
ce
nt
 o
f c
el
ls
 (%
)
*
*
n.s.
Sk-Hep-1 control
Sk-Hep-1 UBXN8
80
60
40
20
0
G1 S G2/M
P
er
ce
nt
 o
f c
el
ls
 (%
) **
*
n.s.
HuH7 control
HuH7 UBXN8
80
60
40
20
0
G1 S G2/M
P
er
ce
nt
 o
f c
el
ls
 (%
)
n.s.
n.s.
n.s.
Cell cycle
Cell cycle
Cell cycle
JOURNAL OF HEPATOLOGY
Journal of Hepatology 2014 vol. 60 j 975–984 981
Research Article
of micro-array based expression proﬁles (see Materials and
methods for details) and real-time qPCR methods (Supplemen-
tary Fig. 3) showed 23 (31%) of the 75 RTGs being abnormally
expressed in HCC tissues compared to adjacent non-tumor tis-
sues or normal tissues (Table 3). Among them, 12 RTGs had never
been reported to be cancer related. Finally noteworthy, RTG in
tumor tissues was signiﬁcantly more frequent (50 genes repeated
only in HCC tissues vs. 11 in non-tumorous tissues, p = 0.0002).
UBXN8 exerts its tumor suppressor role in a TP53 dependent manner
Among the recurrently targeted genes, UBXN8 is one of the newly
discovered RTGs (Fig. 4A) with no known cancer relativity but
presented frequent copy number deletion (28%, 7/25; Table 3).
UBXN8 was signiﬁcantly down-regulated (43%, 21/49; Fig. 4Bi)
in HCC tumor tissues, particularly the HCC tissue with HBV inte-
gration within the intron of UBXN8 (Fig. 4Bii). The low expression
of UBXN8 in HCC tumor tissues was further conﬁrmed byWestern
blot assay (Fig. 4Biii). What is more, dramatically low expression
of UBXN8was found in 7 of the 10 HCC cell lines tested (Fig. 4Biv).
To evaluate the function of UBXN8 in the process of carcino-
genesis, we restored the expression of UBXN8 in 8 HCC cell lines.
The in vitro experiments demonstrated that ectopic expression of
UBXN8 signiﬁcantly slowed down the proliferation of HepG2, Sk-
Hep-1, SMMC7721, and HuH1 cells with wild type TP53 gene [28]
(Supplementary Table 12), but not of PLC/PRF/5, HuH7, SNU449,
and SNU387 whose TP53 were mutated (Fig. 4C, Supplementary
Fig. 4 and Supplementary Table 12). Further ﬂow cytometry
experiments showed that ectopic expression of UBXN8 could
induce G1/S transition retardation in HepG2 and Sk-Hep-1 cells
but not in HuH7 cells (Fig. 4D). Concordantly, we also observed
the up-regulation of p53 and p21CIP1/WAF1 proteins, and down-
regulation of cyclin D1 in HepG2 and Sk-Hep-1 cells after UBXN8
overexpression (Fig. 4E). These results indicated the tumor sup-
pressive activity of UBXN8 by promoting the expression of cell
cycle negative regulators TP53 and p21CIP1/WAF1 in HCC.Discussion
Following the initial discovery of HBV DNA integration, many
studies have investigated its role in HCC carcinogenesis [12,29].
The ability of HBV integration to affect the normal statuses of
nearby host genes was explicit. In the present study, data of
1115 HBV integration sites were collected and analyzed to inves-
tigate the differences of integration between HCC tumor and
adjacent non-tumor tissues that might be related to oncogenicity.
First of all, we conﬁrmed that the break points of the inserted
viral fragment were concentrated within the DR2-DR1 region of
the HBV genome, as previously reported [9]. The DR2 and DR1
sites represent the ends of the partially duplex HBV DNA and
can provide DNA termini for non-homologous end joining (NHEJ)
[29,30]. Consequently, they are more likely to be the initiationFig. 4. UBXN8 exerts its tumor suppressor role in a TP53 dependent manner. (A) The
in 49 paired of HCC tumorous (T), non-tumorous tissues (NT) and 14 normal liver tissu
UBXN8 in T and paired NT. (Biv) Expression of UBXN8 in HCC cell lines. The red dashed li
of MTT assay. (D) The results of ﬂow cytometry cell cycle detection assays. (E) Western blo
UBXN8; ‘control’, cells stable transfected with control vectors. n.s., not signiﬁcant. ⁄p <0
982 Journal of Hepatology 201break points for HBV integration. Since vicinal chromosomal
instabilities have been observed surrounding integration sites
[7], the relatively more even scattering of integrated HBV break
points in HCC tumor tissues may reﬂect the repetitive post-
integration rearrangements of the viral-host junction sequences,
during the process of malignant transformation and rapid
proliferation of hepatocytes. Therefore, we suggested that this
difference is not necessarily related to the greater oncogenic
potency of HBV integration in HCC tumor tissues, but a result
of an inherent feature of cancer cells.
In contrast to the reports by the Ding et al. and Toh et al.,
which concluded that HBV integration into chromosomes 10
and 17 was favored [11,31], no preferential host chromosome
was found in this study. However, we did reveal that HBV inte-
gration events are more likely to occur in genic regions and
gene-dense regions. These regions are characterized by looser
secondary structures, which enable them to be transcriptionally
more active, and this will also make such regions easier to break
and provide the human DNA termini for NHEJ with HBV viral
DNA. On the other hand, the preference of integration sites locat-
ing in these regions increases the potentiality of HBV integration
inﬂuence on host genes.
The active transcription status of host genes nearby integra-
tion sites in non-tumor tissues, but not in tumor tissues, was con-
sistent with the hypothesis that HBV integrates into the open
chromatin conﬁguration more efﬁciently. A potential explanation
is that under normal condition in disease-free liver tissues, the
host genes surrounding the integration sites were supposed to
be transcriptionally more active. Indeed, we found that in most
of the cases, HBV integration prefer to occur near the host genes
which were transcriptionally activated in normal liver cells, like
metabolically related genes. However, in general the aberrant
statuses of such kind of genes usually have little contribution
to tumorigenesis. Only when HBV integration affects the host
genes with cancer related functions, can the hepatocytes with
such integrations obtain growth advantage and eventually
develop into malignant cancer cells, because cancer related host
genes are not always activated in normal liver tissues. For exam-
ple, most of the oncogenes are silent in normal liver tissues.
Therefore, the low expression level of the surrounding host genes
in HCC tumor tissues may be the result of selection during the
process of disease development.
The functional annotation analysis of host genes involved in
HBV integration events showed that functional terms belonging
to four IROF groups were enriched in HCC tissues. Terms related
to negative regulation of cell death and cancer related pathways
are obviously related to HCC development. Aberrations of genes
in terms related to development and differentiation may lead to
hepatocyte de-differentiation so as to promote tumor progress.
Finally aberrations of genes in terms related to transcriptional
regulation may enlarge the range of the genes been affected to
their downstream regulated genes thereby increasing the scope
of inﬂuence of HBV integration events.positions of integrated sites into UBXN8 gene. (Bi) The expression status of UBXN8
es. (Bii) The mRNA level of UBXN8 in tissue No. 85. (Biii) Western blot results of
ne indicates the average expression level of 14 normal liver tissues. (C) The results
t results of several cell cycle related proteins. ‘UBXN8’, HCC cells stable expressing
.05, ⁄⁄p <0.001, ⁄⁄⁄p <0.0001. (This ﬁgure appears in colour on the web.)
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Unlike the HBV infecting animals, such as Woodchuck HBV,
where integrations mainly occurred in certain host genomic
regions, such as the Nmyc2 gene region [32], HBV integration
occurs relatively more randomly in the human genome. However,
there are still a few frequently targeted genes of HBV integration,
such as hTERT and CCNE1. These genes have been shown to be
related to cancer progress in a range of tumors [25–27]. HBV inte-
gration targeting such RTGs has been considered to be the major
oncogenic effect in some studies. In this study, 75 RTGs were
identiﬁed and a signiﬁcant percentage of them showed expres-
sion or function abnormality in cancer cells. Therefore, recurrent
integration by HBV DNA can be considered as an indicator of
being a cancer related gene. Indeed, the in vitro functional restor-
ing experiments implicated that UBXN8, one of the novel RTGs is
a potential tumor suppressor in HCC.
UBXN8 is an Endoplasmic Reticulum (ER) transmembrane
protein. A previous study showed that UBXN8 could tether p97
to the ER membrane for degradation of misfolded proteins
(ERAD) [33]. Insufﬁcient UBXN8 expression would disturb this
process leading to the accumulation of misfolded or unassembled
proteins inside the ER lumen and subsequently induce unfolded
protein response (UPR) or ER stress. It was reported that ER stress
could induce the cytoplasmic localization and degradation of p53
[34,35]. Consistently, our study showed that UBXN8 exerted its
tumor suppressor function only in HCC cell lines with normal
functioning TP53. Additionally, western blot results showed that
exogenous expression of UBXN8 could promote p53 and p21
expression in HepG2 and Sk-Hep-1 with wild type TP53, indicat-
ing UBXN8 function as a tumor-suppressor in a TP53 dependent
manner. Altogether, we proposed that restoration of UBXN8
could remit the ER stress within abnormal cells (like malignant
cells) and thus suppress the degradation of p53, and ﬁnally lead
to the growth inhibition of abnormal cells. However, further
investigation is needed to fully understand the exact relationship
of UBXN8 and ER stress.
In summary, the preference of integration occurring within
genic regions and gene-dense regions, and the characteristic of
containing viral transcription regulating elements within the
inserted HBV fragments endow HBV integration a greater oppor-
tunity to induce crucial oncogenic alterations to host genes. Only
when an HBV integration event targets host genes with onco-
genic functions such as IROFs, can it contribute to the eventual
malignant transformation of hepatocytes. Therefore, the present
study suggests the oncogenicity of HBV integration is determined
by the function of HBV integration targeted host genes in hepato-
cellular carcinoma.Financial support
This study was supported by 973 Program (Grant no.
2012CB518900), the National Natural Science Foundation of
China (Grant no. 81372679), the National S & T Major Project
for Infectious Diseases (Grant no. 2012ZX10004-904), the Leading
Academic Discipline Project of Beijing and the 111 Project.Conﬂict of interest
The authors who have taken part in this study declared that they
do not have anything to disclose regarding funding or conﬂict of
interest with respect to this manuscript.Journal of Hepatology 201Acknowledgement
We thank Doctor Ling Zhang for her enthusiastic help to establish
the HCC tissue specimen database.Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jhep.2013.12.
014.References
[1] Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet
2012;379:1245–1255.
[2] Lu FM, Zhuang H. Management of hepatitis B in China. Chin Med J (Engl)
2009;122:3–4.
[3] Shafritz DA, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC. Integration of
hepatitis B virus DNA into the genome of liver cells in chronic liver disease
and hepatocellular carcinoma. Studies in percutaneous liver biopsies and
post-mortem tissue specimens. N Engl J Med 1981;305:1067–1073.
[4] Koshy R, Koch S, von Loringhoven AF, Kahmann R, Murray K, Hofschneider
PH. Integration of hepatitis B virus DNA: evidence for integration in the
single-stranded gap. Cell 1983;34:215–223.
[5] Chakraborty PR, Ruiz-Opazo N, Shouval D, Shafritz DA. Identiﬁcation of
integrated hepatitis B virus DNA and expression of viral RNA in an HBsAg-
producing human hepatocellular carcinoma cell line. Nature
1980;286:531–533.
[6] Brechot C, Pourcel C, Louise A, Rain B, Tiollais P. Presence of integrated
hepatitis B virus DNA sequences in cellular DNA of human hepatocellular
carcinoma. Nature 1980;286:533–535.
[7] Jiang S, Yang Z, Li W, Li X, Wang Y, Zhang J, et al. Re-evaluation of the
carcinogenic signiﬁcance of hepatitis B virus integration in hepatocarcino-
genesis. PLoS One 2012;7:e40363.
[8] Jiang Z, Jhunjhunwala S, Liu J, Haverty PM, Kennemer MI, Guan Y, et al. The
effects of hepatitis B virus integration into the genomes of hepatocellular
carcinoma patients. Genome Res 2012;22:593–601.
[9] Sung WK, Zheng H, Li S, Chen R, Liu X, Li Y, et al. Genome-wide survey of
recurrent HBV integration in hepatocellular carcinoma. Nat Genet
2012;44:765–769.
[10] Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, et al.
Whole-genome sequencing of liver cancers identiﬁes etiological inﬂuences
on mutation patterns and recurrent mutations in chromatin regulators. Nat
Genet 2012;44:760–764.
[11] Ding D, Lou X, Hua D, Yu W, Li L, Wang J, et al. Recurrent targeted genes of
hepatitis B virus in the liver cancer genomes identiﬁed by a next-generation
sequencing-based approach. PLoS Genet 2012;8:e1003065.
[12] Murakami Y, Saigo K, Takashima H, Minami M, Okanoue T, Brechot C, et al.
Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV
related hepatocellular carcinomas. Gut 2005;54:1162–1168.
[13] Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of
large gene lists using DAVID bioinformatics resources. Nat Protoc
2009;4:44–57.
[14] Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools:
paths toward the comprehensive functional analysis of large gene lists.
Nucleic Acids Res 2009;37:1–13.
[15] Xie Q, Chen X, Lu F, Zhang T, Hao M, Wang Y, et al. Aberrant expression of
microRNA 155 may accelerate cell proliferation by targeting sex-determin-
ing region Y box 6 in hepatocellular carcinoma. Cancer
2012;118:2431–2442.
[16] Chen X, Zhang L, Zhang T, Hao M, Zhang X, Zhang J, et al. Methylation-
mediated repression of microRNA 129-2 enhances oncogenic SOX4 expres-
sion in HCC. Liver Int 2013;33:476–486.
[17] Tamori A, Yamanishi Y, Kawashima S, Kanehisa M, Enomoto M, Tanaka H,
et al. Alteration of gene expression in human hepatocellular carcinoma with
integrated hepatitis B virus DNA. Clin Cancer Res 2005;11:5821–5826.
[18] Wang Y, Lau SH, Sham JS, Wu MC, Wang T, Guan XY. Characterization of HBV
integrants in 14 hepatocellular carcinomas: association of truncated X gene
and hepatocellular carcinogenesis. Oncogene 2004;23:142–148.4 vol. 60 j 975–984 983
Research Article
[19] Chami M, Gozuacik D, Saigo K, Capiod T, Falson P, Lecoeur H, et al. Hepatitis
B virus-related insertional mutagenesis implicates SERCA1 gene in the
control of apoptosis. Oncogene 2000;19:2877–2886.
[20] Wang J, Chenivesse X, Henglein B, Brechot C. Hepatitis B, Virus integration in
a cyclin a gene in a hepatocellular carcinoma. Nature 1990;343:555–557.
[21] Horikawa I, Barrett JC. Cis-Activation of the human telomerase gene (hTERT)
by the hepatitis B virus genome. J Natl Cancer Inst 2001;93:1171–1173.
[22] Shamay M, Agami R, Shaul Y. HBV integrants of hepatocellular carcinoma
cell lines contain an active enhancer. Oncogene 2001;20:6811–6819.
[23] Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, et al.
Integrated analysis of somatic mutations and focal copy-number changes
identiﬁes key genes and pathways in hepatocellular carcinoma. Nat Genet
2012;44:694–698.
[24] Paterlini-Brechot P, Saigo K, Murakami Y, Chami M, Gozuacik D, Mugnier C,
et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in
human liver cancers and recurrently targets human telomerase gene.
Oncogene 2003;22:3911–3916.
[25] Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly
recurrent TERT promoter mutations in human melanoma. Science
2013;339:957–959.
[26] Saigo K, Yoshida K, Ikeda R, Sakamoto Y, Murakami Y, Urashima T, et al.
Integration of hepatitis B virus DNA into the myeloid/lymphoid or mixed-
lineage leukemia (MLL4) gene and rearrangements of MLL4 in human
hepatocellular carcinoma. Hum Mutat 2008;29:703–708.
[27] Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K, et al.
Gene ampliﬁcation CCNE1 is related to poor survival and potential thera-
peutic target in ovarian cancer. Cancer 2010;116:2621–2634.984 Journal of Hepatology 201[28] Gao Y, Lin LP, Zhu CH, Chen Y, Hou YT, Ding J. Growth arrest induced by C75,
A fatty acid synthase inhibitor, was partially modulated by p38 MAPK but
not by p53 in human hepatocellular carcinoma. Cancer Biol Ther
2006;5:978–985.
[29] Bonilla GR, Roberts LR. The role of hepatitis B virus integrations in the
pathogenesis of human hepatocellular carcinoma. J Hepatol
2005;42:760–777.
[30] Bill CA, Summers J. Genomic DNA double-strand breaks are targets for
hepadnaviral DNA integration. Proc Natl Acad Sci U S A
2004;101:11135–11140.
[31] Toh ST, Jin Y, Liu L, Wang J, Babrzadeh F, Gharizadeh B, et al. Deep
sequencing of the hepatitis B virus in hepatocellular carcinoma patients
reveals enriched integration events, structural alterations and sequence
variations. Carcinogenesis 2013;34:787–798.
[32] Ueda K, Wei Y, Ganem D. Activation of N-myc2 gene expression by cis-acting
elements of oncogenic hepadnaviral genomes: key role of enhancer II.
Virology 1996;217:413–417.
[33] Madsen L, Kriegenburg F, Vala A, Best D, Prag S, Hofmann K, et al. The tissue-
speciﬁc Rep8/UBXD6 tethers p97 to the endoplasmic reticulum membrane
for degradation of misfolded proteins. PLoS One 2011;6:e25061.
[34] Qu L, Huang S, Baltzis D, Rivas-Estilla AM, Pluquet O, Hatzoglou M, et al.
Endoplasmic reticulum stress induces p53 cytoplasmic localization and
prevents p53-dependent apoptosis by a pathway involving glycogen
synthase kinase-3beta. Genes Dev 2004;18:261–277.
[35] Pluquet O, Qu LK, Baltzis D, Koromilas AE. Endoplasmic reticulum stress
accelerates p53 degradation by the cooperative actions of Hdm2 and
glycogen synthase kinase 3beta. Mol Cell Biol 2005;25:9392–9405.4 vol. 60 j 975–984
